Asaf Danziger

2017

In 2017, Asaf Danziger earned a total compensation of $4.3M as Chief Executive Officer at NovoCure, a 173% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$643,668
Option Awards$1,533,150
Salary$698,439
Stock Awards$1,144,000
Other$292,331
Total$4,311,588

Danziger received $1.5M in option awards, accounting for 36% of the total pay in 2017.

Danziger also received $643.7K in non-equity incentive plan, $698.4K in salary, $1.1M in stock awards and $292.3K in other compensation.

Rankings

In 2017, Asaf Danziger's compensation ranked 2,315th out of 14,666 executives tracked by ExecPay. In other words, Danziger earned more than 84.2% of executives.

ClassificationRankingPercentile
All
2,315
out of 14,666
84th
Division
Manufacturing
810
out of 5,768
86th
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
104
out of 856
88th
Industry group
Surgical, Medical, And Dental Instruments And Supplies
54
out of 528
90th
Industry
Surgical and Medical Instruments and Apparatus
34
out of 333
90th
Source: SEC filing on April 20, 2018.

Danziger's colleagues

We found four more compensation records of executives who worked with Asaf Danziger at NovoCure in 2017.

2017

William Doyle

NovoCure

Chairman

2017

Wilhelmus Groenhuysen

NovoCure

Chief Financial Officer

2017

Eilon Kirson

NovoCure

Chief Scientific Officer

2017

Michael Ambrogi

NovoCure

Chief Operating Officer

News

You may also like